1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Ajani JA, D'Amico TA, Almhanna K, Bentrem
DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, et
al: Gastric cancer, version 3.2016, NCCN Clinical Practice
Guidelines in Oncology. J Natl Compr Canc Netw. 14:1286–1312. 2016.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang
DW and Zhang RG: Randomized clinical trial on the combination of
preoperative irradiation and surgery in the treatment of
adenocarcinoma of gastric cardia (AGC) - report on 370 patients.
Int J Radiat Oncol Biol Phys. 42:929–934. 1998. View Article : Google Scholar : PubMed/NCBI
|
5
|
Hazard L, O'Connor J and Scaife C: Role of
radiation therapy in gastric adenocarcinoma. World J Gastroenterol.
12:1511–1520. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Macdonald JS, Smalley SR, Benedetti J,
Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA,
Gunderson LL, Jessup JM, et al: Chemoradiotherapy after surgery
compared with surgery alone for adenocarcinoma of the stomach or
gastroesophageal junction. N Engl J Med. 345:725–730. 2001.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Lee J, Lim DH, Kim S, Park SH, Park JO,
Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, et al: Phase III trial
comparing capecitabine plus cisplatin versus capecitabine plus
cisplatin with concurrent capecitabine radiotherapy in completely
resected gastric cancer with D2 lymph node dissection: The ARTIST
trial. J Clin Oncol. 30:268–273. 2012. View Article : Google Scholar
|
8
|
Minn AY, Hsu A, La T, Kunz P, Fisher GA,
Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, et al:
Comparison of intensity-modulated radiotherapy and 3-dimensional
conformal radiotherapy as adjuvant therapy for gastric cancer.
Cancer. 116:3943–3952. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Freidlin B, Jiang W and Simon R: The
cross-validated adaptive signature design. Clin Cancer Res.
16:691–698. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Freidlin B and Simon R: Adaptive signature
design: an adaptive clinical trial design for generating and
prospectively testing a gene expression signature for sensitive
patients. Clin Cancer Res. 11:7872–7878. 2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
Tang Z, Zeng Q, Li Y, Zhang X, Ma J, Suto
MJ, Xu B and Yi N: Development of a radiosensitivity gene signature
for patients with soft tissue sarcoma. Oncotarget. 8:27428–27439.
2017.PubMed/NCBI
|
12
|
Molinaro AM, Simon R and Pfeiffer RM:
Prediction error estimation: A comparison of resampling methods.
Bioinformatics. 21:3301–3307. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Moertel CG, Childs DS Jr, Reitemeier RJ,
Colby MY Jr and Holbrook MA: Combined 5-fluorouracil and
supervoltage radiation therapy of locally unresectable
gastrointestinal cancer. Lancet. 2:865–867. 1969. View Article : Google Scholar : PubMed/NCBI
|
14
|
Lowy AM, Feig BW, Janjan N, Rich TA,
Pisters PW, Ajani JA and Mansfield PF: A pilot study of
preoperative chemoradiotherapy for resectable gastric cancer. Ann
Surg Oncol. 8:519–524. 2001. View Article : Google Scholar : PubMed/NCBI
|
15
|
Rödel C, Liersch T, Becker H, Fietkau R,
Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M,
Raab HR, et al German Rectal Cancer Study Group: Preoperative
chemo-radiotherapy and postoperative chemotherapy with fluorouracil
and oxaliplatin versus fluorouracil alone in locally advanced
rectal cancer: Initial results of the German CAO/ARO/AIO-04
randomised phase 3 trial. Lancet Oncol. 13:679–687. 2012.
View Article : Google Scholar
|
16
|
Hong YS, Nam BH, Kim KP, Kim JE, Park SJ,
Park YS, Park JO, Kim SY, Kim TY, Kim JH, et al: Oxaliplatin,
fluorouracil, and leucovorin versus fluorouracil and leucovorin as
adjuvant chemotherapy for locally advanced rectal cancer after
preoperative chemoradiotherapy (ADORE): An open-label, multicentre,
phase 2, randomised controlled trial. Lancet Oncol. 15:1245–1253.
2014. View Article : Google Scholar : PubMed/NCBI
|
17
|
Dikken JL, Jansen EP, Cats A, Bakker B,
Hartgrink HH, Kranenbarg EM, Boot H, Putter H, Peeters KC, van de
Velde CJ, et al: Impact of the extent of surgery and postoperative
chemoradiotherapy on recurrence patterns in gastric cancer. J Clin
Oncol. 28:2430–2436. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Smalley SR, Benedetti JK, Haller DG,
Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson
JA, Jessup JM, et al: Updated analysis of SWOG-directed intergroup
study 0116: A phase III trial of adjuvant radiochemotherapy versus
observation after curative gastric cancer resection. J Clin Oncol.
30:2327–2333. 2012. View Article : Google Scholar : PubMed/NCBI
|
19
|
Liu GF, Bair RJ, Bair E, Liauw SL and
Koshy M: Clinical outcomes for gastric cancer following adjuvant
chemoradiation utilizing intensity modulated versus
three-dimensional conformal radiotherapy. PLoS One. 9:e826422014.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Wang X, Li G, Zhang Y, Bai S, Xu F, Wei Y
and Gong Y: Single-arc volumetric-modulated arc therapy (sVMAT) as
adjuvant treatment for gastric cancer: Dosimetric comparisons with
three-dimensional conformal radiotherapy (3D-CRT) and
intensity-modulated radiotherapy (IMRT). Med Dosim. 38:395–400.
2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Dahele M, Skinner M, Schultz B, Cardoso M,
Bell C and Ung YC: Adjuvant radiotherapy for gastric cancer: A
dosimetric comparison of 3-dimensional conformal radiotherapy,
tomotherapy and conventional intensity modulated radiotherapy
treatment plans. Med Dosim. 35:115–121. 2010. View Article : Google Scholar
|
22
|
Jameson JL and Longo DL: Precision
medicine - personalized, problematic, and promising. N Engl J Med.
372:2229–2234. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Martens FK, Kers JG and Janssens AC:
External validation is only needed when prediction models are worth
it (Letter commenting on: J Clin Epidemiol. 2015;68:25–34). J Clin
Epidemiol. 69:249–250. 2016. View Article : Google Scholar
|
24
|
Bleeker SE, Moll HA, Steyerberg EW,
Donders AR, Derksen-Lubsen G, Grobbee DE and Moons KG: External
validation is necessary in prediction research: A clinical example.
J Clin Epidemiol. 56:826–832. 2003. View Article : Google Scholar : PubMed/NCBI
|
25
|
Bijlsma MW, Brouwer MC, Bossuyt PM,
Heymans MW, van der Ende A, Tanck MW and van de Beek D: Risk scores
for outcome in bacterial meningitis: Systematic review and external
validation study. J Infect. 73:393–401. 2016. View Article : Google Scholar : PubMed/NCBI
|
26
|
Wang J, Chen C, Li HF, Jiang XL and Zhang
L: Investigating key genes associated with ovarian cancer by
integrating affinity propagation clustering and mutual information
network analysis. Eur Rev Med Pharmacol Sci. 20:2532–2540.
2016.PubMed/NCBI
|